DelveInsight’s Advanced Ovarian Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Ovarian Cancer treatment.

Oncolytics Biotech reveals promising survival data for pelareorep, an innovative immunotherapy, showing significant benefits ...

Paclitaxel given once per week with trastuzumab and pertuzumab was well tolerated. Perhaps most notably, the incidence of febrile neutropenia was 0% as opposed to 13.8% with docetaxel and dual ...

A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, ...

Weekly paclitaxel therapy is effective and well tolerated in women with metastatic breast cancer. 33-39 By using a weekly administration schedule for both agents, we sought to further exploit the ...

Sirolimus and paclitaxel-coated balloons showed comparable safety and effectiveness in treating CAD across diverse lesion ...

Index line of therapy (LOT) components included IV paclitaxel/nab-paclitaxel and all chemotherapy agents (capecitabine, carboplatin, cisplatin, cyclophosphamide, doxorubicin, epirubicin, eribulin ...

The addition of carboplatin to paclitaxel improved pathologic complete response and EFS with no increase in secondary malignancies among patients with triple-negative breast cancer, randomized ...

“Oral paclitaxel and encequidar is the first world taxane to demonstrate superiority in radiologically confirmed tumor response rate, with reduced neuropathy and alopecia compared to IV ...

Oral paclitaxel was the first oral taxane, a novel alternative to the standard IV chemotherapy, to elicit a higher overall response rate (ORR) than IVPac.